health


Epidemic sovereignty? Contesting investment treaty claims arising from coronavirus measures
Allegedly arbitrary or disproportionate measures, albeit in the public interest, provide regular grist for the mill of investment treaty arbitration.
Covid-19: Why India doesn’t need to worry about investor-State dispute settlement claims
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
The Comprehensive and Progressive Agreement for the Trans-Pacific Partnership: Data exclusivity and access to biologics
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
Intellectual property rights: Potential implications of the DCFTA for access to medicine
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
US trade deal ‘could flood Britain with toxic cosmetics’
Campaigners fear that EU rules banning dangerous chemicals will be relaxed to allow American companies into UK market.
Caroline Lucas: Coronavirus – and why we should all be worried about the US trade deal
Corporate-led trade deals put us all in danger when it comes to tacking future health crises, writes Caroline Lucas MP.
India offers US dairy, chicken access in bid for elusive trade deal with Trump
India has offered to partially open up its poultry and dairy markets in a bid for a limited trade deal during US President Donald Trump’s first official visit.
Trump will insist NHS pays more for drugs in trade deal, says ambassador
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
The bully in the lunchroom: The US moves to weaken Mexico’s new junk food labeling law
Even though US negotiators were forced by public opposition to remove language explicitly banning front-of-package graphic labels from New NAFTA, other provisions of concern remain in the trade deal.